Catalyst Capital Advisors LLC Trims Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Catalyst Capital Advisors LLC lowered its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 23.5% in the second quarter, HoldingsChannel reports. The firm owned 65 shares of the biopharmaceutical company’s stock after selling 20 shares during the period. Catalyst Capital Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $34,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Creative Financial Designs Inc. ADV boosted its holdings in Regeneron Pharmaceuticals by 9.5% in the first quarter. Creative Financial Designs Inc. ADV now owns 220 shares of the biopharmaceutical company’s stock valued at $139,000 after purchasing an additional 19 shares during the last quarter. Private Trust Co. NA boosted its holdings in Regeneron Pharmaceuticals by 13.1% in the first quarter. Private Trust Co. NA now owns 164 shares of the biopharmaceutical company’s stock valued at $104,000 after purchasing an additional 19 shares during the last quarter. Proficio Capital Partners LLC lifted its holdings in Regeneron Pharmaceuticals by 6.2% during the 1st quarter. Proficio Capital Partners LLC now owns 327 shares of the biopharmaceutical company’s stock worth $207,000 after buying an additional 19 shares during the last quarter. Cove Private Wealth LLC lifted its holdings in Regeneron Pharmaceuticals by 4.5% during the 1st quarter. Cove Private Wealth LLC now owns 460 shares of the biopharmaceutical company’s stock worth $292,000 after buying an additional 20 shares during the last quarter. Finally, Marino Stram & Associates LLC lifted its holdings in Regeneron Pharmaceuticals by 5.3% during the 2nd quarter. Marino Stram & Associates LLC now owns 396 shares of the biopharmaceutical company’s stock worth $208,000 after buying an additional 20 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 0.4%

Shares of Regeneron Pharmaceuticals stock opened at $577.95 on Friday. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The business’s 50 day simple moving average is $576.32 and its 200-day simple moving average is $562.62. The stock has a market capitalization of $61.26 billion, a price-to-earnings ratio of 14.57, a PEG ratio of 1.80 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $943.83.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping analysts’ consensus estimates of $8.43 by $4.46. The business had revenue of $3.68 billion for the quarter, compared to analysts’ expectations of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The business’s quarterly revenue was up 3.6% on a year-over-year basis. During the same period in the prior year, the firm earned $11.56 EPS. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.87%.

Analyst Ratings Changes

A number of research firms have commented on REGN. Jefferies Financial Group increased their target price on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a “buy” rating in a report on Wednesday, August 27th. Citigroup increased their target price on Regeneron Pharmaceuticals from $650.00 to $660.00 and gave the stock a “buy” rating in a report on Monday, October 13th. Truist Financial reduced their target price on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating on the stock in a report on Monday, August 11th. Royal Bank Of Canada increased their target price on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a “sector perform” rating in a report on Monday, August 4th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $850.00 target price on shares of Regeneron Pharmaceuticals in a report on Thursday. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $802.35.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.